John H. Boey
ABSTRACT
Toxic nodular goiters comprise toxic multinodular goiter (TMNG) and the solitary autonomously functioning thyroid nodule
(AFTN). Preferential growth of actively secreting, TSH-independent thyroid follicles gives rise to palpable nodules. Although most
patients remain euthyroid, some gradually develop biochemical, and later clinical, toxicity. The latter is more common with enlarging
thyroid mass and advancing age, and in endemic goiter areas. The declining incidence of toxic goiters parallels the overall reduction
in goiters, especially in endemic regions. AFTN and TMNG presently account for about 10% to 20% of all cases of hyperthyroidism.
Definitive therapy is indicated for frank toxicity, obstructive symptoms, and suspicion of malignancy. The choice between surgery
and radio iodine ablation should be individualized according to the general health and age of the patient, the severity of toxicity, the goiter
size andpresence of obstruction, the possibility of malignancy, and prior treatment. Radioiodine ispreferredin patients who are medically
unfit or elderly, especially if they have mild toxicity or a small gland, and in those who relapse after thyroidectomy. Despite the relatively
high dosages administered, hyperthyroidism may not be controlled for many months, and repeat applications are necessary in about a
quarter of patients. Late hypothyroidism occurs quite commonly after radioiodine ablation of solitary AFTNs but less often after treatment
for TMNG.
Subtotal thyroidectomy for TMNG and lobectomyfor AFTN rapidly alleviate toxic symptoms and remove the goiter. It is most suitable
in healthy and young individuals, those with obstructing goiters and possibly malignant nodules. Most patients are rendered euthyroid
but an increasing incidence of late hypothyroidism has been recognized following surgery for TMNG. Primary operations are very safe
but higher complication rates attend reexplorations.
166
Journal of the Hong Kong Medical Association Vol. 42, No.3, 1990
and 1954 (19). In iodine-sufficient areas, TMNG now accounts
for about 4% to 15% of hyperthyroidism (29,30). In a recent
survey of 201 hyperthyroid patients in New Zealand (31), 170
had Graves' disease, 21 TMNG, and only 10 had AFTN. On the
other hand, in iodine-deficient areas such as South America,
Iran and parts of Europe (25), TMNG still accounts for up to
one-half of hyperthyroid conditions. In a series of 630 surgical
patients, the relative incidence of Graves' disease, TMNG and
solitary AFTN was 58.2%, 36.2% and 5.6% respectively (24). This
epidemiological data supports the major promoting role of
iodine insufficiency and TSH stimulation in its pathogenesis,
and suggests that the recent declining incidence of toxic
goiters in endemic areas is related to increased dietary iodine
intake.
Solitary AFTN is seen inroughly 5% of patients with dominant
sporadic nodules (22,32). However, most lesions are nontoxic,
and Hamburger (22) encountered only one toxic AFTN for
every 50 Graves' lesions. In endemic goiter areas, toxic AFTNs
can account for up to one third of hyperthyroid cases (18).
CLINICAL PRESENTATION
Because a TMNG evolves from a preexisting nontoxic
goiter, sporadic TMNG, unlike other forms of hyperthyroidism,
is more prevalent among patients in the seventh and later
decades of life (19). Given the earlier onset of TMNG in
endemic goiter areas, toxicity appears about a decade earlier
but still only after a 13 to 15 years period of evolution (18).
Women are affected in about 80% of cases (19).
Unlike Graves' disease, hyperthyroidism in TMNG develops insidiously. Seldom is the condition ushered in by a
dramatic flurry of thyrotoxic symptoms. Only after the diagnosis
is made are mild toxic symptoms retrospectively ascribed to
this indolent condition. As sporadic cases occur mainly in
elderly patients, cardiac symptoms (atrial fibrillation or congestive heart failure) predominate. Non-specific symptoms
such as weight loss, increasingly labile control of diabetes
mellitus or delayed recovery from acute illnesses might raise
this diagnostic possibility to the astute physician. Less commonly, impaired swallowing or stridor reflects tracheal compression by a large goiter or one in a retrosternal location.
Toxic AFTNs, although frequently existing by the fourth
and fifth decades of life, usually become symptomatic only a
decade later (19,22). Whereas the female to male sex ratio in
sporadic nontoxic autonomous nodules is about 14.9:1, a lower
ratio of 5.9:1 is observed in toxic AFTNs (22). A larger
proportion of men (33%) are affected (22), and this is even more
so in endemic regions (33). Most patients with AFTN are
clinically and biochemically euthyroid (22,24), and a dominant
nodule is often the sole finding (21,24). Tachycardia, anxiety
and weight loss suggest the possibility of hyperthyroidism, and
the absence of a bilateral goiter and eye signs point to the
correct diagnosis.
DIAGNOSTIC STUDIES
Investigations should detect hyperthyroidism, verify autonomous function, and delineate the location, size and nature
of the nodules. Relying on a single biochemical test will fail to
diagnose hyperthyroidism in some cases. Screening tests
should include a serum RIA T4, T3 uptake and FTI. Accompanying the gradual decrease in radioiodine uptake (RAIU) in
the general population, the 24 hours RAIU in TMNG has
declined simultaneously, from about 35% to 26% in one longterm study (19). The low sensitivity of RAIU in diagnosing
hyperthyroidism is apparent given the finding that 22 of 35
patients with large toxic goiters had a RAIU of less than 30%
168
RECURRENCE
The major advantage of subtotal thyroidectomy for TMNG
is that not only is hyperthyroidism alleviated but the risk of
recurrence is extremely low. Endemic AFTN or TMNG relapsed
in between 0% (24) and 4.2% of patients (18) compared with
none after surgery in sporadic goiter areas (19). Because of the
dissociation between follicular growth and function, destruction
of only hyperfunctioning tissue by selective surgery or
radioiodine treatment may not prevent recurrent goiter formation from hypofunctioning nodules (6). Six of seven goiters
that recurred after selective resection arose from macroscopically normal lobes that were not resected (11). This supports
the role of subtotal thyroidectomy in the operative management
of TMNG.
The value of thyroxine supplement to decrease the likelihood of relapse after thyroidectomy is unsettled. Thyroxine
has little to offer after resection of AFTN where the recurrence
rate is less than 1% (8). Most recurrences in TMNG probably
arise from the proliferation of residual autonomous follicles.
This is suggested by the observation that 10% of patients who
were euthyroid postoperatively had a persistently negative
TRH test (11). As such, not only would these patients not be
expected to respond to exogenous thyroxine but there is the
possibility of producing iatrogenic hyperthyroidism (11). In
endemic goiter areas, however, the iodine metabolism of the
residual TSH-dependent thyroid tissue may be impaired, and
exogenous thyroxine supplement may abolish postoperative
170
REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
171